A single blood draw that screens for many cancers at once moved a step closer to American clinics this week.
Natera announced on October 9 that the Food and Drug Administration has granted Breakthrough Device designation to its multi-cancer early detection assay, a blood test that analyses fragments of cell-free DNA for signals of cancer. In granting the designation, the FDA reviewed data covering 12 cancer types, weighing how often the test correctly detects cancer, how often it correctly clears healthy patients, and how accurately it points to where in the body a signal originates.
The designation is not an approval, and the test is not yet on the market. What it does is put the program on a faster regulatory track — more frequent interaction with FDA reviewers and priority handling — reserved for technologies that may offer more effective diagnosis of life-threatening conditions. A pivotal study is planned involving 25,000 average-risk adults aged 40 and over who are already scheduled for colonoscopy, comparing the blood test’s performance against standard screening.
The clinical logic is straightforward. Many cancers are found only after symptoms appear, when treatment is hardest; screening tests exist for just a handful of cancer types. “Too many cancers are diagnosed after they’ve progressed, simply because limited screening options exist,” a senior company medical officer said in announcing the designation.
The hard questions come next: how many false alarms the test generates, whether earlier detection actually saves lives rather than merely advancing the date of diagnosis, and who pays. Breakthrough status means those questions now get asked on an accelerated clock.
Related reading: Gut Bacteria May Reveal How Fast the Brain Is Aging, UCLA Study Suggests · Drug-Resistant Candida Auris Cases More Than Doubled in Two Years, CDC Data Show · FDA Decision Day Arrives for a Colon Cancer Immunotherapy Combination
